**Supplemental Digital Content 4.** Proportion of participants with rSBA titers ≥1:128 at baseline (Day 0) and Day 30 (Per Protocol Analysis Set).

|  |  |  |  |
| --- | --- | --- | --- |
| **Serogroup** | **Time point**  | **MenACYW-TT****(N=458)** | **MenACWY-CRM****(N=460)** |
|  |  | **n/M** | **% (95% CI)** | **n/M** | **% (95% CI)** |
| **A** | Day 0 | 88/183 | 48.1 (40.7, 55.6) | 89/173 | 51.4 (43.7, 59.1) |
|  | Day 30 | 177/178 | 99.4 (96.9, 100.0) | 178/178 | 100.0 (97.9, 100.0) |
| **C** | Day 0 | 12/183 | 6.6 (3.4, 11.2) | 8/173 | 4.6 (2.0, 8.9) |
|  | Day 30 | 178/178 | 100.0 (97.9, 100.0) | 166/178 | 93.3 (88.5, 96.5) |
| **W** | Day 0 | 3/183 | 1.6 (0.3, 4.7) | 15/173 | 8.7 (4.9, 13.9) |
|  | Day 30 | 178/178 | 100.0 (97.9, 100.0) | 176/178 | 98.9 (96.0, 99.9) |
| **Y** | Day 0 | 36/183 | 19.7 (14.2, 26.2) | 37/173 | 21.4 (15.5, 28.3) |
|  | Day 30 | 178/178 | 100.0 (97.9, 100.0) | 177/178 | 99.4 (96.9, 100.0) |

CI, confidence interval; M, number of participants with a valid serology result for the particular serogroup and time point; n, number of participants experiencing the endpoint listed; N, the total number of participants in the Per-Protocol Analysis Set.